Publicacións en colaboración con investigadores/as de Instituto Valenciano de Oncologia (12)

2021

  1. Management of localized muscle-invasive bladder cancer from a multidisciplinary perspective: Current position of the Spanish oncology genitourinary (Sogug)working group

    Current Oncology, Vol. 28, Núm. 6, pp. 5084-5100

  2. Recommended procedures and responsibilities for radiosurgery (SRS) and extracranial stereotactic body radiotherapy (SBRT): report of the SEOR in collaboration with the SEFM

    Clinical and Translational Oncology, Vol. 23, Núm. 7, pp. 1281-1291

2019

  1. Outcomes and prognostic factors in intermediate-risk prostate cancer: multi-institutional analysis of the Spanish RECAP database

    Clinical and Translational Oncology, Vol. 21, Núm. 7, pp. 900-909

  2. Survival after biochemical failure in prostate cancer treated with radiotherapy: Spanish Registry of Prostate Cancer (RECAP) database outcomes

    Clinical and Translational Oncology, Vol. 21, Núm. 8, pp. 1044-1051

2018

  1. Adjuvant versus salvage radiotherapy in prostate cancer: multi-institutional retrospective analysis of the Spanish RECAP database

    Clinical and Translational Oncology, Vol. 20, Núm. 2, pp. 193-200

  2. Advanced imaging techniques in evaluation of colorectal cancer

    Radiographics, Vol. 38, Núm. 3, pp. 740-765

2016

  1. GRAY-B: An open label multicenter phase-2 GEM study on ipilimumab and radiation in patients with melanoma and brain metastases

    Annals of Oncology, Vol. 27, pp. vi383

  2. The number of risk factors is the strongest predictor of prostate cancer mortality: multi-institutional outcomes of an extreme-risk prostate cancer cohort

    Clinical and Translational Oncology, Vol. 18, Núm. 10, pp. 1026-1033

2015

  1. Nomogramme für die Prognose eines biochemischen Rezidivs beim Prostatakarzinom nach Strahlentherapie und Androgendeprivationstherapie

    Strahlentherapie und Onkologie, Vol. 191, Núm. 10, pp. 792-800

2014

  1. Infrastructures, treatment modalities, and workload of radiation oncology departments in Spain with special attention to prostate cancer

    Clinical and Translational Oncology, Vol. 16, Núm. 5, pp. 447-454

2013

  1. Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO study

    British Journal of Cancer, Vol. 108, Núm. 12, pp. 2565-2572

2010

  1. Spanish radiobiological pattern of care in lung cancer: A GOECP/SEOR study

    Clinical and Translational Oncology, Vol. 12, Núm. 4, pp. 292-298